Lacosamid Zentiva

Lacosamide, the active ingredient in Lacosamid Zentiva, is an anticonvulsant presented as an oral tablet for oral use. It is used as adjunctive therapy in patients with partial‑onset seizures and primary generalized tonic‑clonic seizures.

GNH USA supplies Lacosamid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Primary generalized tonic‑clonic seizures: provides adjunctive seizure control in combination with other antiepileptics.

Lacosamide may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Nausea: mild to moderate stomach upset. - Headache: intermittent or persistent pain. - Fatigue: feeling unusually tired. - Diplopia: double vision. - Tremor: mild shaking of limbs. Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including PR interval prolongation. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: difficulty breathing in severe cases.

When prescribing Lacosamid Zentiva, clinicians should consider several safety measures. - Cardiac monitoring: assess ECG for PR interval prolongation, especially in patients with cardiac disease. - Renal impairment: adjust dose in patients with severe renal dysfunction. - Hepatic impairment: use caution and consider dose reduction in liver disease. - Pregnancy: avoid use unless benefits outweigh potential risks, as safety data are limited. - Discontinuation: do not stop abruptly; taper to reduce seizure recurrence risk. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, influencing its efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lacosamide plasma levels, decreasing effectiveness. - Concomitant sodium channel blockers (e.g., carbamazepine, phenytoin): increase risk of cardiac conduction abnormalities. - Dual antiplatelet therapy: heightened bleeding risk when combined with anticoagulants. Moderate Interactions (Monitor Closely): - Hormonal contraceptives: may lower contraceptive efficacy, requiring additional methods. - Antidepressants (e.g., SSRIs): monitor for increased risk of suicidal thoughts. - Diuretics: watch for electrolyte disturbances that could affect cardiac rhythm.